ES2295386T3 - Uso de fucanos en el tratamiento de adherencias, artritis y soriasis. - Google Patents

Uso de fucanos en el tratamiento de adherencias, artritis y soriasis. Download PDF

Info

Publication number
ES2295386T3
ES2295386T3 ES02758008T ES02758008T ES2295386T3 ES 2295386 T3 ES2295386 T3 ES 2295386T3 ES 02758008 T ES02758008 T ES 02758008T ES 02758008 T ES02758008 T ES 02758008T ES 2295386 T3 ES2295386 T3 ES 2295386T3
Authority
ES
Spain
Prior art keywords
fucan
composition
fucoidan
fucano
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02758008T
Other languages
English (en)
Spanish (es)
Inventor
John K. Jackson
Helen M. Burt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2295386T3 publication Critical patent/ES2295386T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES02758008T 2001-08-29 2002-08-29 Uso de fucanos en el tratamiento de adherencias, artritis y soriasis. Expired - Lifetime ES2295386T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31536201P 2001-08-29 2001-08-29
US315362P 2001-08-29

Publications (1)

Publication Number Publication Date
ES2295386T3 true ES2295386T3 (es) 2008-04-16

Family

ID=23224048

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02758008T Expired - Lifetime ES2295386T3 (es) 2001-08-29 2002-08-29 Uso de fucanos en el tratamiento de adherencias, artritis y soriasis.

Country Status (15)

Country Link
US (3) US6812220B2 (cg-RX-API-DMAC7.html)
EP (1) EP1420801B1 (cg-RX-API-DMAC7.html)
JP (2) JP4758063B2 (cg-RX-API-DMAC7.html)
KR (2) KR100910246B1 (cg-RX-API-DMAC7.html)
CN (2) CN101028283A (cg-RX-API-DMAC7.html)
AT (1) ATE376835T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002325113B2 (cg-RX-API-DMAC7.html)
CA (1) CA2458853C (cg-RX-API-DMAC7.html)
DE (1) DE60223262T2 (cg-RX-API-DMAC7.html)
DK (1) DK1420801T3 (cg-RX-API-DMAC7.html)
ES (1) ES2295386T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001876A (cg-RX-API-DMAC7.html)
NZ (2) NZ532015A (cg-RX-API-DMAC7.html)
PT (1) PT1420801E (cg-RX-API-DMAC7.html)
WO (1) WO2003018033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
SI1539157T1 (sl) * 2002-09-18 2013-11-29 Trustees Of The University Of Pennsylvania Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
US8137688B2 (en) 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7465766B2 (en) 2004-01-08 2008-12-16 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US6982298B2 (en) 2003-01-10 2006-01-03 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8138265B2 (en) 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8221758B2 (en) * 2003-03-06 2012-07-17 Cellmid Limited Anti-midkine antibody for preventing post-laparotomy adhesions
EP1631265A2 (en) * 2003-05-30 2006-03-08 Arc Pharmaceuticals, Inc. Use of various agents for inhibiting fibrous adhesions
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト, インコーポレイテッド 経強膜送達
JPWO2005089800A1 (ja) * 2004-03-17 2008-01-31 株式会社ロコモジェン hsHRD3を含む医薬組成物
CA2572804C (en) * 2004-07-09 2013-04-02 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR100752244B1 (ko) * 2005-02-16 2007-08-27 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 약제 조성물
US20060210515A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Hair growth formula
US20070020358A1 (en) * 2005-03-18 2007-01-25 Mower Thomas E Sports drink concentrate
US20060210514A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin protection and moisturizing compositions and method of making the same
US20060210688A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Dehydrated sports drink powder
US20060210496A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Compositions for skin protection from ultraviolet damage
US7776365B2 (en) * 2005-03-18 2010-08-17 Sakura Properties, Llc Article with skin protecting and moisturizing compound
US7749545B2 (en) 2005-03-18 2010-07-06 Sakura Properties, Llc Fucoidan compositions and methods for dietary and nutritional supplements
US20060210692A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Baby food composition
US20060210697A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Infant formula composition
US7666448B2 (en) * 2005-03-18 2010-02-23 Sakura Properties, Llc Skin cleansing article
DK1871353T3 (da) 2005-04-15 2011-04-04 Einstein Coll Med Vitamin k til forebyggelse eller behandling af hududslæt sekundært til anti-EGFR-terapi
US20070003669A1 (en) * 2005-06-02 2007-01-04 Troy Kearl Fucoidan delivery system
WO2007028256A2 (en) * 2005-09-09 2007-03-15 Les Biotechnologies Oceanova Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
FR2897538B1 (fr) 2006-02-23 2008-05-02 Univ Paris Descartes Utilisation de fucanes a des fins de greffe, d'ingenierie et de regeneration osseuses
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
JP4814677B2 (ja) * 2006-03-31 2011-11-16 株式会社荏原製作所 基板保持装置および研磨装置
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
ES2585483T3 (es) 2008-02-13 2016-10-06 The Cleveland Clinic Foundation Mejora molecular de la matriz extracelular y métodos de uso
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US8410180B2 (en) 2008-04-30 2013-04-02 The Cleveland Clinic Foundation Methods to treat urinary incontinence
WO2010109736A1 (ja) * 2009-03-25 2010-09-30 国立大学法人鳥取大学 軟骨生成促進剤および軟骨損傷由来疾病の予防治療剤
JO3676B1 (ar) * 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
KR101528265B1 (ko) * 2010-04-16 2015-06-11 코웨이 주식회사 베타-라파콘을 유효성분으로 포함하는 주름개선용 화장료 조성물
EP2734213B1 (en) * 2011-07-19 2018-06-06 Baxalta GmbH Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
JP2018510905A (ja) * 2015-02-16 2018-04-19 エグザンシャル 皮膚障害の予防又は治療のための組成物
PT3448421T (pt) * 2016-04-29 2022-01-14 Univ Leland Stanford Junior Métodos e composições para a prevenção e tratamento de aderências cirúrgicas
US12186334B2 (en) 2018-07-27 2025-01-07 ARC Medical Inc. High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
MX2021000864A (es) 2018-07-27 2021-03-26 Arc Medical Devices Inc Fucanos altos en sulfato para el tratamiento de adhesiones fibrosas.
AU2020230466B2 (en) 2019-03-05 2021-05-13 Arc Medical Devices Inc. Systems and methods for tangential flow filtration of viscous compositions
CN111617030B (zh) * 2020-05-22 2021-09-07 广东药科大学 壳寡糖口服液及其在制备减肥药物中的应用
WO2025166450A1 (en) * 2024-02-05 2025-08-14 ARC Medical Inc. Compositions, devices, systems and methods relating to improvement of range of motion in joints

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971848A (en) * 1970-12-21 1976-07-27 Kimitsu Chemical Laboratory Co. Ltd. Lubricating composition for mucosa or epidermis
JPS58147064A (ja) 1982-02-25 1983-09-01 Fuji Electric Co Ltd トランジスタ
EP0293826A3 (en) 1987-06-02 1989-05-10 Stichting REGA V.Z.W. Therapeutic and prophylactic application of sulfated polysaccharides against aids
JPS6431707A (en) 1987-07-28 1989-02-02 Nikko Chemicals Dermal agent for external use
JPH0714850B2 (ja) 1987-09-29 1995-02-22 喜郎 板谷 化粧料
JPH01313433A (ja) 1988-06-13 1989-12-18 Nippon Koutai Kenkyusho:Kk 抗hiv剤
JP2853165B2 (ja) * 1989-05-29 1999-02-03 味の素株式会社 体組織癒着防止膜
FR2648463B1 (fr) * 1989-06-14 1993-01-22 Inst Fs Rech Expl Mer Polysaccharides sulfates, agent anticoagulant et agent anticomplementaire obtenus a partir de fucanes d'algues brunes et leur procede d'obtention
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
US5318890A (en) * 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
JP3403496B2 (ja) 1993-09-24 2003-05-06 株式会社ヤクルト本社 抗潰瘍剤およびヘリコバクター・ピロリの定着阻害剤
JP3545789B2 (ja) * 1993-09-30 2004-07-21 味の素ファルマ株式会社 腹腔内癒着防止剤
FR2772618B1 (fr) * 1997-12-18 2000-02-18 Ifremer Utilisation de fucane comme regulateur de la reconstruction des tissus conjonctifs
JP2002526556A (ja) * 1998-10-02 2002-08-20 ジェンザイム・コーポレーション 癒着の防止方法
JP4267106B2 (ja) * 1998-10-15 2009-05-27 株式会社クラレ 癒着防止用材料
JP2001052309A (ja) 1999-08-06 2001-02-23 Alps Electric Co Ltd 薄膜磁気ヘッドおよびその製造方法
SE0001631D0 (sv) * 2000-05-04 2000-05-04 Sahltech Ab New use

Also Published As

Publication number Publication date
DE60223262T2 (de) 2008-08-14
JP2009280597A (ja) 2009-12-03
CA2458853C (en) 2010-10-19
MXPA04001876A (es) 2004-06-15
DK1420801T3 (da) 2008-03-03
HK1066482A1 (en) 2005-03-24
DE60223262D1 (de) 2007-12-13
NZ532015A (en) 2006-12-22
KR20090019926A (ko) 2009-02-25
JP4758063B2 (ja) 2011-08-24
AU2002325113B2 (en) 2006-10-26
WO2003018033A1 (en) 2003-03-06
JP2005508893A (ja) 2005-04-07
EP1420801A1 (en) 2004-05-26
US20050074496A1 (en) 2005-04-07
KR100910246B1 (ko) 2009-07-31
EP1420801B1 (en) 2007-10-31
PT1420801E (pt) 2008-01-17
CN101028283A (zh) 2007-09-05
CN1547478A (zh) 2004-11-17
KR20040032992A (ko) 2004-04-17
NZ547609A (en) 2008-07-31
US6812220B2 (en) 2004-11-02
CA2458853A1 (en) 2003-03-06
CN1319540C (zh) 2007-06-06
ATE376835T1 (de) 2007-11-15
US7163930B2 (en) 2007-01-16
US20030064958A1 (en) 2003-04-03
US20050119216A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
US6812220B2 (en) Pharmaceutical compositions and methods relating to fucans
AU2002325113A1 (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
ES2729826T3 (es) Composiciones farmacéuticas y métodos relacionados para inhibir adherencias fibrosas o enfermedad inflamatoria usando fucanos con bajo contenido de sulfato
JP2007504273A (ja) 種々の作用剤を用いた、線維性癒着の抑制に関する医薬組成物及び方法
JP2007504273A5 (cg-RX-API-DMAC7.html)
US20070238697A1 (en) Pharmaceutical compositions and methods relating to fucans
AU2007200318B2 (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
EP1870105A1 (en) Use of fucans in the treatment of psoriasis
HK1066482B (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
HK1108566A (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
US20170252367A1 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans